# Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

> **NCT07022483** · PHASE3 · RECRUITING · sponsor: **Daiichi Sankyo** · enrollment: 710 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Trastuzumab Deruxtecan
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT07022483
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2032-03-23
- **Final completion:** 2032-03-23
- **Target enrollment:** 710 (ESTIMATED)
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07022483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07022483, "Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07022483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*